Objective: To systematically review the efficacy and safety of voriconazole what was used to prevent the invasive fungal
infection by patients after hematopoietic stem- cell transplantation. Methods: The PubMed, Medline, Cochrane Library, EMbase,
CNKI, CBM, Wangfang, VIP databases were searched to find out the randomized controlled trials about the efficacy and safety of
voriconazole as anti-fungal prophylaxis of invasive fungal infection after hematopoietic stem-cell transplantation. Quality and extracted
information of the clinical trials were evaluated. Meta-analysis was performed using RevMan 5.3 software. Results: 4 RCTs were
included, involving 1 325 patients. Results of Meta-analysis showed: voriconazole could reduce IFI after hematopoietic stem-cell
transplantation[RR=0.57, 95% CI(0.38, 0.86), P<0.01]and decrease the incidence of ADR[RR=0.78, 95% CI(0.64, 0.95), P=
0.01]. There was no statistical significance in mortality among voriconazole, fluconzole and itraconzole[RR=0.84, 95% CI(0.58,
1.20), P=0.33]. Conclusion: Voriconazole as anti- fungal prophylaxis of invasive fungal infection can effectively reduce the
occurrence of IFI and ADR after hematopoietic stem-cell transplantation.